Category: Pharma News
-
Milestone Pharma wins FDA nod for self-administered nasal spray for PSVT
The at-home treatment is designed to manage acute symptomatic episodes outside of emergency healthcare settings.
-
AC Immune’s stock rises with positive Phase II data
Interim Phase II data suggest its vaccine candidate may slow progression, a potential first in Parkinson’s treatment.
-
ASH25: Tessera’s gene writing hits curative thresholds in sickle cell
New preclinical data show Gene Writing tech exceeding key efficacy benchmarks for sickle cell disease and in vivo CAR-T generation.
-
Dicot Pharma unlocks sustained ED effect with LIB-01
Swedish company reveals how LIB-01, an erectile dysfunction therapy, works via the melanocortin system, offering sustained effects and possible hope for non-responders.
-
Iolyx and Théa partner on $280 million autoimmune eye drug deal
Concurrently with the collaboration deal for ILYX-002 for autoimmune-associated dry eye disease, Iolyx announced a $15 million Series B financing.
-
The $1 trillion blind spot: Bridging the gap in women’s health
Dr. Christian Tidona, founder and CEO of BioMed X, on why women’s health is critically underfunded and how a new initiative aims to change that.
-
Pharvaris stock rises following positive Phase III topline data
The company’s oral drug deucrictibant significantly sped up symptom relief in the Phase III trial, positioning it for 2026 regulatory filings.
-
Regeneron and Tessera ink $275 mil pact for gene editing therapy
The companies will co-develop TSRA-196, a potential one-time genetic treatment for alpha-1 antitrypsin deficiency.
-
Levron Medical emerges with new approach to treating heart failure
Following first-in-human results and new funding, the company prepares for a clinical study at Sheba Medical Center.
-
FDA expands Grifols’ antithrombin therapy in children
The US regulator approves expanded Thrombate III label, offering new treatment options for children with hereditary antithrombin deficiency.
-
UK launches nuclear-driven push into precision cancer medicine
Recycled nuclear materials to fuel next-generation targeted alpha treatments in a major UK initiative.
-
Adagene & Third Arc Bio forge $845 million T-cell engager pact
Adagene licenses its SAFEbody tech to Third Arc Bio for two masked CD3 T cell engagers, netting $5million upfront, and upto $840 million in milestone payments.
Latest posts
-
Navigating the Risks and Rewards of Biomarker-Based Surrogates and Accelerated Approval
The risks and rewards of biomarker-based surrogates are crucial for optimizing clinical trial outcomes and guiding effective treatments.
-
ASH25: Gallop’s LYT-200 shows unprecedented survival in AML
The company’s execs talk about the striking efficacy and safety signals seen in Phase I data, the science behind the molecule, and their vision for transforming AML therapy.
-
Promis reports first human evidence of aβ oligomer reduction by pmn310
PMN310 demonstrates dose-dependent reduction of amyloid-beta oligomers in human CSF, marking a key milestone in Alzheimer’s treatment development.
-
Urologic Health secures $11 million for non-invasive bladder monitoring
Urologic Health raises $11million seed funding to advance a catheter-free bladder monitoring platform toward FDA clearance and US market entry.
-
Novo Nordisk’s denecimig cuts bleeding in hemophilia A regardless of inhibitors
Phase III trial shows once‑monthly and once‑weekly denecimig (Mim8) significantly reduces annualized bleeding rate versus standard care, with up to 95% of patients bleed‑free.